Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy

Conference: PAGE
Division: Cognigen


Compound A is a potent and highly selective non-steroidal mineralocorticoid receptor (MR) antagonist being developed for the treatment of diabetic nephropathy and other potential indications. Richly sampled PK data collected in phase 1 studies exhibited complex PK profiles for Compound A (secondary and tertiary peaks as well as prolonged absorption profiles following initial peak concentrations in conjunction with dose-dependent reductions in exposure with increasing doses) and its major metabolite (Metabolite B; slow formation and elimination).

Population Approach Group in Europe (PAGE), June 6-9 2017, Budapest, Hungary

By Tadakatsu Nakamura, Tomoko Kubota, David Jaworowicz, Kuan-Ju Lin, Atsuhiro Kawaguchi